Treatment of arterial pulmonary hypertension with epoprostenol (intravenous prostacyclin) improves survival and quality of life, but the need for an implanted central venous catheter is associated with frequent complications, that often (as in the case of infection or dislodgment) are serious and require catheter replacement. Treprostinil is a prostacyclin analogue suitable for continuous subcutaneous administration. We report the successful transition from intravenous epoprostenol to subcutaneous treprostinil in four patients with severe pulmonary hypertension who suffered from serious complications associated with the epoprostenol infusion system.

**Key words:** Pulmonary hypertension. Prostacyclin. Treprostinil.

**INTRODUCTION**

Intravenous prostacyclin (epoprostenol) is effective treatment for pulmonary arterial hypertension (PAH), demonstrating clinical and hemodynamic improvement and increased survival.1-4 Because of its short half-life (2-5 min), however, it must be administered by continuous infusion through a central venous catheter connected to a perfusion pump. Serious complications related to the infusion system frequently occur, requiring the system to be changed and increasing the morbidity and mortality of the patients.5

Treprostinil, a stable prostacyclin analogue with a longer half-life (3-4 h), can be administered by continuous subcutaneous infusion. In a recent study, treprostinil showed short-term clinical efficacy (12 weeks) for the treatment of severe pulmonary hypertension without serious complications related to the infusion system.6 Based on these results, we contemplated a transition to subcutaneous treatment in clinically stable patients receiving intravenous treatment and presenting complications associated with the infusion system, as an alternative to replacement. We report the cases of four patients under epoprostenol treatment who presented infectious complications and were transitioned to subcutaneous treprostinil.

**PATIENTS AND METHODS**

Between November 2001 and April 2002, four women with severe pulmonary hypertension, one with primary pulmonary hypertension, two associated with lupus erythematosus and the other with scleroderma, presented serious infectious complications. In three
The baseline characteristics of each patient are described in Table 1. In three patients (patients 1, 2 and 3) epoprostenol dosage had not been changed in the previous 3 months. Two experienced infection of the Hickman catheter caused by *Staphylococcus aureus* and *Pseudomonas aeruginosa*, respectively, presenting fever, reddening of the surrounding skin tissue and purulent drainage through the catheter orifice, making it necessary to withdraw the catheter. The third was wearing a Port-A-Cath® system, which was withdrawn because of pneumococcal sepsis. Epoprostenol was then administered through a peripheral line at the same doses.

The fourth patient was diagnosed of pulmonary hypertension following hospitalization for severe right-sided heart failure and required treatment with epoprostenol, dobutamine and diuretics. Following stabilization, she presented multiple subcutaneous abscesses caused by *Staphylococcus aureus*, a situation in which insertion of a central venous catheter is unadvisable.

The changes in the epoprostenol and treprostinil infusion rate during transition are described in Table 2. Epoprostenol was withdrawn between the fourth and sixth day. The baseline epoprostenol dose was 10 to 13 ng/kg/min and the dose of treprostinil after transition was 12.5 to 15 ng/kg/min, i.e., 15%-20% greater. The transition was well tolerated, and there were no signs or symptoms of prostacyclin excess or insufficiency, or significant changes in blood pressure or heart rate.

The functional class and exercise capacity of each patient as measured by NYHA and the six-minute walking distance, respectively, before and after the treatment change are listed in Table 1. In the medium-term follow-up (3 to 8 months), no patient experienced clinical deterioration and the clinical parameters remained similar. In two patients (Patients 1 and 2), the values were similar. Patient 3 showed a decrease in the distance walked and a worsening of NYHA functional class, mainly attributed to severe pain at the subcutaneous infusion site, since no other functional deterioration was observed. Patient 4 was NYHA Class IV and did not perform the baseline six-minute test. However, the treatment change was carried out after clinical stabilization and at the sixth month of follow-up, her functional class and exercise capacity had improved.

**RESULTS**

The baseline characteristics of each patient are described in Table 1.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Age (years)</th>
<th>Sex</th>
<th>PH Type</th>
<th>Diagnosis time</th>
<th>Treatment time</th>
<th>NYHA</th>
<th>6 min</th>
<th>sPAPe</th>
<th>Associated complication</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>46</td>
<td>F</td>
<td>Scleroderma</td>
<td>143</td>
<td>128</td>
<td>II</td>
<td>492</td>
<td>500</td>
<td>72 Pneumococcal sepsis</td>
</tr>
<tr>
<td>2</td>
<td>28</td>
<td>F</td>
<td>Lupus erythematos</td>
<td>18</td>
<td>12</td>
<td>III</td>
<td>408</td>
<td>425</td>
<td>59 Staphylococcal infection</td>
</tr>
<tr>
<td>3</td>
<td>29</td>
<td>F</td>
<td>Primary</td>
<td>61</td>
<td>37</td>
<td>I</td>
<td>570</td>
<td>480</td>
<td>89 Localized Pseudomonas infection</td>
</tr>
<tr>
<td>4</td>
<td>38</td>
<td>F</td>
<td>Lupus erythematos</td>
<td>4</td>
<td>2</td>
<td>IV</td>
<td>63</td>
<td>434</td>
<td>45 Multiple soft tissue abscesses</td>
</tr>
</tbody>
</table>

*Diagnosis time: time between diagnosis and transition (months). Treatment time: treatment time with epoprostenol until time of transition (months). PH indicates pulmonary hypertension; NYHA, New York Heart Association class; 6 min, walking distance during the 6-minute test; pre, corresponds to values before treatment change (meters); post, corresponds to values after change (third month, except for Patient 4, sixth month; sPAPe, systolic pulmonary artery pressure estimated by echocardiography in the pre-transition visit (89 mm Hg); F, female.*
Infusion site pain was the most important adverse effect observed. One of the patients required a slower dosage increase, and three required specific analgesic treatment, one with local measures (cold and topical anti-inflammatory agents), and two with oral drugs (gabapentin).

**DISCUSSION**

The clinical progress of our patients demonstrates that transition from intravenous to subcutaneous prostacyclin can be safely performed in stable patients and can achieve good medium-term clinical progress.

Although pulmonary arterial hypertension continues to be an incurable condition, treatment with intravenous prostacyclin has led to a significant change in the disease in terms of clinical improvement and survival. Nevertheless, the use of continuous intravenous perfusion is associated with potentially serious complications requiring catheter replacement, and the outcome is sometimes fatal. The incidence of catheter infection is estimated at 0.22-0.68 per patient-year, with that of sepsis estimated at 0-0.39 per patient-year. Other frequent complications are catheter dislodgement, thrombosis and paradoxical embolism in patients with intracardiac shunts. Furthermore, because of the short half-life of epoprostenol (3-5 min), any interruption in treatment can result in sudden worsening of pulmonary hypertension, leading to syncope and a life-threatening condition.

New forms of treatment for pulmonary hypertension have been developed in recent years. Subcutaneous (treprostinil) and inhaled (iloprost) prostacyclin have proven to be effective in pulmonary arterial hypertension (in particular, in its primary and collagen-disease related forms), in terms of clinical and functional class improvement, as observed in short-term follow-up (12 weeks).

The advantages of treprostinil over epoprostenol are its longer half-life (3-4 h) and subcutaneous delivery system, which is free of serious complications and more convenient to administer; no deaths directly attributable to complications derived from the infusion system have been reported. The impact on the natural course of the disease is unknown, however, although indirect data suggest that it can increase survival. As reported recently by Vachiéry et al., patients under epoprostenol treatment can be safely transitioned to subcutaneous treprostinil treatment at the physician’s discretion. In that study, 8 patients with pulmonary arterial hypertension receiving various doses of epoprostenol (3.5-75 ng/kg/min) were changed to subcutaneous treprostinil (3-65 ng/kg/min) over a varying time period (1-4 days).

In our patients, the transition was completed between the fourth and the sixth day, with changes in the infusion rate every 12 h. The final treprostinil dosage was somewhat higher (between 15% and 20%) than the previous epoprostenol dosage. In the medium-term follow-up (3 to 8 months), no clinical deterioration was observed and the four patients were stable at the time of writing. The adverse effects reported most frequently with treprostinil are local pain and inflammation (over 80%). The pain is generally well controlled with topical measures such as cold and local anti-inflammatory drugs, or oral treatment with paracetamol, anti-inflammatories, gabapentin or short courses of steroids. Three patients in our series required analgesia, two of them with oral gabapentin. In one of them transition was slower due to local pain, although it was completed successfully.

In summary, subcutaneous treprostinil is an option for patients with pulmonary hypertension who are currently under intravenous epoprostenol treatment and who experience complications associated with the infusion system. The transition from one treatment to the other is safe, provided the patient’s underlying disease is stable.

**REFERENCES**


